31.2%
of Arizona adults are obese
13
cancer types linked to obesity
7×
higher diabetes risk
40%+
obesity in rural AZ communities

$1T+
estimated annual cost of obesity-related healthcare in the U.S.
The Truth About Weight Gain in Arizona
For decades, Arizonans were told that "fat-free" foods were healthy. We were told processed snacks were better than real food. Flavored yogurt, diet sodas, chemical sweeteners, low-fat frozen meals, and ultra-processed convenience foods were marketed as safe everyday choices.
And now? Arizona is living through a quiet metabolic crisis. More than 31% of Arizona adults — nearly 1 in 3 — are now classified as obese, and the numbers are far worse in rural regions and tribal communities across the state.
Arizona's growing cities brought fast food on every corner, longer commutes, more sedentary jobs, fewer walkable neighborhoods, and more reliance on ultra-processed convenience foods. The desert landscape that once defined a healthy outdoor lifestyle has given way to a sprawling, car-dependent environment that works against metabolic health at every turn.
"This is not happening to 'other people.' This is happening in every Arizona city, suburb, and rural community."
In rural Arizona and tribal communities, obesity rates climb above 40% of adults. The Navajo Nation, San Carlos Apache, and other Indigenous communities face some of the highest obesity and diabetes rates in the nation — a legacy of displacement, food deserts, and a healthcare system that failed them for generations.
Section 3
Phoenix experiences 110+ days per year above 100°F — conditions that make sustained outdoor exercise genuinely dangerous for most of the year. Unlike temperate states where walking, cycling, and outdoor activity are realistic daily habits, Arizona's summers are a metabolic trap: stay inside, stay sedentary, stay cool.
The Phoenix metro is one of the most car-dependent major metros in the United States, with walkability scores among the lowest of any large American city. Average one-way commutes run 26–27 minutes — time that compounds into elevated cortisol, disrupted sleep schedules, and increased reliance on fast, calorie-dense drive-through food.
In rural Arizona and tribal lands, the problem is more acute: food deserts, limited healthcare access, and environments entirely dependent on processed, shelf-stable foods. The Navajo Nation, San Carlos Apache, and White Mountain Apache communities face some of the highest obesity and Type 2 diabetes rates in the nation — a direct consequence of food environment, not character.
"When the research talks about 'environmental contributors to obesity,' this is what it means in Arizona. It's not a lack of character. It's a geography built for the wrong outcomes."
110+
days/year above 100°F in Phoenix
Makes outdoor exercise dangerous for most of the year
~37
Phoenix Walk Score (out of 100)
One of the least walkable major metros in the U.S.
26 min
Average Arizona daily commute
One way — adds daily cortisol and fast-food reliance
40%+
Obesity in some AZ tribal communities
A consequence of food deserts and systemic under-investment
Highly processed foods were engineered to be addictive, inexpensive, and convenient. Arizona's rapid suburban growth created car-dependent communities where walking is limited, fresh food is expensive, and fast food is everywhere.
Over time, the body changes. For many Arizona residents, weight gain becomes more than calories in and calories out. Hunger signals change. Cravings intensify. "Food noise" becomes constant — that relentless mental chatter about food that never stops.
The body begins defending excess weight, making traditional dieting frustrating, exhausting, and often unsuccessful.
Speak with a licensed provider from the comfort of your Arizona home. No judgment. Semaglutide from $149/month · Tirzepatide from $169/month.
No membership fee · No contract · No annual commitment · No required prepayment · Free shipping · Free consultation
Your exact price depends on your prescribed dose. Your provider confirms it before you pay.
Section 4
Research on weight stigma consistently shows that people with obesity face widespread discrimination in healthcare, employment, and social settings. The paradoxical effect: rather than motivating change, stigma leads to avoidance — of doctors, of gyms, of any situation that might invite judgment.
Source: Puhl & Heuer, Obesity Reviews 2009; JAMA 2021
The majority of Arizona adults with obesity have already attempted weight loss — multiple times, often seriously. They've tracked calories. Done boot camps. Paid for programs. At some point, the rational response to repeated failure is to stop trying. That's not a character flaw — that's learned helplessness, and it has a neurological basis.
Source: Mann et al., American Psychologist 2007
Without addressing the underlying hormonal and neurological drivers of appetite, virtually every diet-and-exercise intervention results in the body fighting back — lowering metabolic rate, intensifying hunger signals, and restoring lost weight within 1–5 years for the vast majority of people. The problem was never effort. The problem was strategy.
95%
of dieters regain weight within 5 years
UCLA meta-analysis, Mann et al. 2007
↓40%
metabolic rate reduction after diet-only weight loss
Leibel et al., NEJM 1995
2013
AMA declares obesity a chronic disease
AMA Resolution 420, 2013
CDC Surveillance Data · 2023
Arizona adult obesity rate vs. neighboring and comparison states — CDC BRFSS 2023
Arizona vs. Western States — Adult Obesity Rate
CDC Behavioral Risk Factor Surveillance System, 2023
Source: CDC BRFSS, 2023. Arizona adult obesity rate: 31.2% — nearly 1 in 3 adults.
31.2%
of Arizona adults are classified as obese
40%+
obesity in some Arizona rural & tribal communities
$9.3B
estimated annual obesity-related healthcare cost in Arizona
What Obesity Actually Causes
Obesity isn't a standalone condition — it's a driver of serious, life-altering diseases that affect every system in the body.
Type 2 Diabetes
7× higher risk
Obesity is the single strongest modifiable risk factor for Type 2 diabetes. In Arizona, diabetes prevalence runs ~10.5% of adults — with far higher rates in rural and tribal communities.
Source: CDC, 2023; NEJM SELECT Trial, 2023
Heart Disease & Stroke
2× higher risk
Excess body weight raises blood pressure, LDL cholesterol, and inflammatory markers — all direct contributors to cardiovascular disease and stroke risk.
Source: JAMA, 2020; AHA Scientific Statement
13 Types of Cancer
Cancer #2 cause in AZ
The National Cancer Institute links 13 cancer types to excess body weight — including breast, colon, pancreatic, kidney, and uterine cancers. Obesity accounts for ~40% of all U.S. cancer diagnoses.
Source: NCI; NEJM 2016
Sleep Apnea
10× more common
Excess neck and airway fat is the primary driver of obstructive sleep apnea. Treating obesity directly reduces sleep apnea severity — often dramatically, without a CPAP machine.
Source: Sleep Medicine Reviews; SURMOUNT-OSA Trial, 2024
Osteoarthritis
4× higher risk
Every pound of excess body weight adds 4 pounds of pressure to the knee joints. For Arizona's active outdoor community — hikers, golfers, cyclists — joint health directly determines quality of life.
Source: Arthritis Foundation; NEJM 2023
Fatty Liver Disease
Affects 25% of AZ adults
Non-alcoholic fatty liver disease now affects an estimated 1 in 4 American adults. It is almost entirely driven by excess body fat — and GLP-1 medications have shown dramatic improvement in liver health in clinical trials.
Source: NEJM Evidence, NEJM 2023
Section 5 · What the Research Shows
The University of Arizona — right here in state — is home to one of the Southwest's leading research programs on metabolic disease, hunger signaling, and obesity biology. UA Health Sciences and Banner University Medical Center have produced research fundamental to understanding why conventional diets fail long-term.
The core finding across this body of research: the hypothalamus — a brain region roughly the size of an almond — orchestrates the body's entire energy balance system. In individuals with obesity, this system is not "broken." It has been recalibrated to a higher setpoint. The brain is defending against perceived starvation.
This is why willpower-based approaches fail at scale. Willpower operates in the prefrontal cortex. Appetite regulation operates in the hypothalamus. These systems are not equals — the hypothalamus wins. Every time. Until you change the signals it's receiving.
"Obesity is a neurobiological condition first, and a behavioral one second. Treating it as purely behavioral is why most interventions fail." — Banner University Medical Center Research Overview
Source: UA Health Sciences, BUMC Metabolic Disease Program; Leibel et al., NEJM 1995
Section 6 · Food Noise
"Food noise" is the clinical term for the persistent, intrusive preoccupation with food that many people with obesity experience throughout the day. It's not emotional eating. It's not boredom. It's a neurological background process — a near-constant awareness of food, hunger, and eating that consumes cognitive bandwidth every hour.
Research into hunger gene pathways shows this is driven by the same hypothalamic circuits governing energy homeostasis. Leptin resistance — common in obesity — means the brain fails to register fullness correctly, leaving the appetite system in a state of perpetual low-grade alarm.
GLP-1 receptor agonists like semaglutide and tirzepatide work, in large part, by quieting this noise at the neurological level. Patients consistently report that after starting therapy, food stops occupying their thoughts the way it once did. That's not willpower. That's pharmacology targeting the right system.
GLP-1
works at the hypothalamic level — not willpower
~80%
of patients report reduced food noise on therapy
Source: Wilding et al., NEJM 2021 (STEP 1); Friedman JM, Nature 2000
American Medical Association · 2013
For the first time in history, medicine has a direct treatment for the biology of obesity — not just the symptoms. GLP-1 medications work on the hormone pathways that control hunger, fullness, blood sugar, and food noise.
Patients who spent decades fighting their own biology — and losing — are seeing 15–22% body weight loss in clinical trials. Not because they suddenly found willpower. Because medicine finally addressed the actual problem.
The Medical Breakthrough
GLP-1 medications — including semaglutide and tirzepatide — work directly on the brain's appetite control center. They don't suppress your appetite through willpower. They change the biology of hunger itself.
Patients describe "food noise" going quiet. The constant mental chatter about eating — what to eat, when to eat, why they ate that — simply stops. For many, it's the first relief they've had in years.
15–20%
average body weight lost
7×
reduced diabetes risk
20%
cardiovascular event reduction
49%
reduced sleep apnea severity
GLP-1 Science
Semaglutide from $149/month · Tirzepatide from $169/month
No membership fee · No contract · No annual commitment · No required prepayment · Free shipping · Free consultation
Your exact price depends on your prescribed dose. Your provider confirms it before you pay.
Transparent Pricing
At Arizona Trim Clinic, we believe access to gold-standard telehealth care should not depend on your Arizona zip code, how far you are from a city, or your income.
Semaglutide from $149/month · Tirzepatide from $169/month
No membership fee · No contract · No annual commitment · No required prepayment · Free shipping · Free consultation
Your exact price depends on your prescribed dose. Your provider confirms it before you pay.
Frequently Asked Questions
Obesity is classified as a chronic disease by the American Medical Association, the World Health Organization, and all major medical bodies. It has a complex etiology involving genetics, neurobiology, environment, and metabolic adaptation. While lifestyle factors influence it, labeling it a choice significantly oversimplifies the biology.
Yes. The cardiovascular and metabolic risk data applies across the weight spectrum. Even modest excess weight in the overweight BMI range carries meaningfully elevated risk for hypertension, insulin resistance, and certain cancers. Earlier intervention produces better long-term outcomes.
GLP-1 receptor agonists (semaglutide, tirzepatide) work at the neurological level — reducing food noise, slowing gastric emptying, and improving insulin sensitivity. They address the biological drivers of hunger and weight regain that make traditional diets unsustainable for most people long-term.
GLP-1 therapy is FDA-approved for adults with a BMI of 27 or above who have at least one weight-related condition (hypertension, Type 2 diabetes, dyslipidemia), or a BMI of 30 or above regardless of comorbidities. A licensed provider reviews your history to determine eligibility.
For GLP-1 medication management, telehealth delivers equivalent clinical outcomes to in-person care for the vast majority of patients. The medication, dosing protocol, monitoring, and physician oversight are identical — the only difference is no waiting room and no commute.
Yes — in multiple ways. Extreme heat severely limits safe outdoor exercise for 4–5 months per year, increases sedentary behavior, disrupts sleep quality, and elevates cortisol — a hormone that promotes visceral fat storage. This is one reason Arizona's obesity rates are structurally high relative to outdoor-friendly climates.
References
This page is for informational purposes only. Results vary. Medical eligibility required. Not every patient qualifies for GLP-1 treatment. Speak with a licensed provider.
Get the medical care you were always owed. Free consultation with a licensed provider. Semaglutide from $149/month · Tirzepatide from $169/month.
No membership fee · No contract · No annual commitment · No required prepayment · Free shipping · Free consultation
Your exact price depends on your prescribed dose. Your provider confirms it before you pay.
Results vary. Medical eligibility required. GLP-1 medications are not appropriate for everyone. Speak with a licensed provider to determine if treatment is right for you.
Read the original source for the topic described below. These references support medical education, not Arizona Trim Clinic pricing, service claims or patient outcomes. Their inclusion does not imply endorsement, affiliation or review of Arizona Trim Clinic.
Observed associations between BMI and certain cancers in a UK cohort; not evidence that GLP-1 treatment prevents cancer.
The harms of weight stigma, the complexity of obesity and the need for respectful, evidence-based care.
Individual eligibility, prescription evaluation, medication risks, lifestyle measures and variation in treatment response.
STEP 1 trial: weight change and gastrointestinal adverse events with semaglutide 2.4 mg plus lifestyle intervention in adults without diabetes.
SURMOUNT-1 trial: dose-specific weight change and adverse events in adults with obesity or overweight without diabetes.
Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. The Lancet. 2014.
Research published in The Lancet reported associations between higher BMI and risk of several cancers. An observational association does not establish that weight-loss medication prevents cancer.
Read the original research: Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adultsRubino F, Puhl RM, Cummings DE, et al. Nature Medicine. 2020.
Research published in Nature Medicine reported an international consensus on addressing weight stigma. This is a consensus statement, not a clinical trial proving an individual treatment outcome.
Read the original research: Joint international consensus statement for ending stigma of obesityWilding JPH, Batterham RL, Calanna S, et al. New England Journal of Medicine. 2021.
Research published in New England Journal of Medicine reported mean weight change of −14.9% with semaglutide and −2.4% with placebo at 68 weeks in the studied population. This is not a prediction of an individual patient's result or evidence for a compounded product.
Read the original research: Once-Weekly Semaglutide in Adults with Overweight or ObesityJastreboff AM, Aronne LJ, Ahmad NN, et al. New England Journal of Medicine. 2022.
Research published in New England Journal of Medicine reported mean weight change of −20.9% at the 15 mg dose and −3.1% with placebo at 72 weeks under the treatment-regimen estimand. Different estimands can yield different figures; trial results do not establish superiority over every treatment or predict clinic outcomes.
Read the original research: Tirzepatide Once Weekly for the Treatment of ObesityThis is general education, not individualized medical advice. Prescription treatment requires evaluation by a licensed provider. Eligibility, medication and dosing depend on individual circumstances. Research on a specific approved product or dose should not be generalized to compounded products or to every patient.
South Florida Trim Clinic is where the Trim Clinic Network began. Arizona Trim Clinic carries that approach forward with personalized care from independent licensed medical providers. These providers evaluate patients and make individualized treatment and prescribing decisions. No membership fees ever. Care is provided through telehealth where legally and clinically appropriate; eligibility and treatment depend on individual needs.